Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy

[1]  I. Weissman,et al.  CD47 Blockade by Hu5F9‐G4 and Rituximab in Non‐Hodgkin's Lymphoma , 2018, The New England journal of medicine.

[2]  Purvesh Khatri,et al.  Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes , 2017, Cell.

[3]  I. Weissman,et al.  Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity , 2017, Proceedings of the National Academy of Sciences.

[4]  K. Weiskopf.  Cancer immunotherapy targeting the CD47/SIRPα axis. , 2017, European journal of cancer.

[5]  J. Danska,et al.  SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin , 2017, Nature.

[6]  H. Matlung,et al.  The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer , 2017, Immunological reviews.

[7]  D. Felsher,et al.  MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.

[8]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[9]  Daniel H. Lackner,et al.  A generic strategy for CRISPR-Cas9-mediated gene tagging , 2015, Nature Communications.

[10]  G. Superti-Furga,et al.  Gene essentiality and synthetic lethality in haploid human cells , 2015, Science.

[11]  R. Ubink,et al.  Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting , 2015, mAbs.

[12]  S. Lohse,et al.  Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing , 2015, Cancer Immunology Research.

[13]  Christine Mayr,et al.  Alternative 3'UTRs act as scaffolds to regulate membrane protein localization , 2015, Nature.

[14]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[15]  Jens-Peter Volkmer,et al.  Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies , 2013, Science.

[16]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[17]  F. Bertucci,et al.  CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction , 2011, Proceedings of the National Academy of Sciences.

[18]  J. Dye,et al.  Ebola virus entry requires the cholesterol transporter Niemann-Pick C1 , 2011, Nature.

[19]  Ash A. Alizadeh,et al.  Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47 , 2010, Science Translational Medicine.

[20]  Ash A. Alizadeh,et al.  Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma , 2010, Cell.

[21]  P. Parren,et al.  In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. , 2010, Cancer research.

[22]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[23]  I. Weissman,et al.  CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.

[24]  Ton N Schumacher,et al.  Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers , 2009, Nature Methods.

[25]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[26]  A. Kehlen,et al.  Isolation of an isoenzyme of human glutaminyl cyclase: retention in the Golgi complex suggests involvement in the protein maturation machinery. , 2008, Journal of molecular biology.

[27]  P. Coffer,et al.  Cytokine-induced inside-out activation of FcalphaR (CD89) is mediated by a single serine residue (S263) in the intracellular domain of the receptor. , 2001, Blood.

[28]  A. Ullrich,et al.  Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. , 1999, Blood.

[29]  T. Kuijpers,et al.  Membrane surface antigen expression on neutrophils: a reappraisal of the use of surface markers for neutrophil activation. , 1991, Blood.

[30]  H. Ploegh,et al.  An improved biochemical method for the analysis of HLA-class I antigens. Definition of new HLA-class I subtypes. , 1986, Human immunology.